{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:46:59Z","timestamp":1772160419034,"version":"3.50.1"},"reference-count":19,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Influenza Resp Viruses"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>During the early phase of the coronavirus disease 2019 (COVID\u201019), remdesivir was only approved for hospitalized patients. Our institution developed hospital\u2010based, outpatient infusion centers for selected hospitalized patients with COVID\u201019 who had clinical improvement to allow for early dismissal. The outcomes of patients who transitioned to complete remdesivir in the outpatient setting were examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective study of all hospitalized adult patients with COVID\u201019 who received at least one dose of remdesivir from November 6, 2020, to November 5, 2021, at one of the Mayo Clinic hospitals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 3029 hospitalized patients who received treatment with remdesivir for COVID\u201019, the majority (89.5%) completed the recommended 5\u2010day course. Among them, 2169 (80%) patients completed treatment during hospitalization, whereas 542 (20.0%) patients were dismissed to complete remdesivir in outpatient infusion centers. Patients who completed the treatment in the outpatient setting had lower odds of death within 28\u2009days (aOR 0.14, 95% CI 0.06\u20130.32,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). However, their rate of subsequent hospital encounters within 30\u2009days was higher (aHR 1.88, 95% CI 1.27\u20132.79,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). Among patients treated with remdesivir only in the inpatient setting, the adjusted odds of death within 28\u2009days were significantly higher among those who did not complete the 5\u2010day course of remdesivir (aOR 2.07, 95% CI 1.45\u20132.95,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study describes the clinical outcomes of a strategy of transitioning remdesivir therapy from inpatient to outpatient among selected patients. Mortality was lower among patients who completed the 5\u2010day course of remdesivir.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/irv.13136","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T09:44:25Z","timestamp":1684316665000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical outcomes of COVID\u201019 treated with remdesivir across the continuum of care"],"prefix":"10.1111","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8308-3264","authenticated-orcid":false,"given":"Christina G.","family":"Rivera","sequence":"first","affiliation":[{"name":"Department of Pharmacy Mayo Clinic  Rochester Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Supavit","family":"Chesdachai","sequence":"additional","affiliation":[{"name":"Division of Public Health, Infectious Diseases, and Occupational Medicine Mayo Clinic  Rochester Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan W.","family":"Draper","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Mayo Clinic  Rochester Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard F.","family":"Arndt","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Mayo Clinic Health System  Eau Claire Wisconsin USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin C.","family":"Mara","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences Mayo Clinic  Rochester Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Gonzalez Suarez","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension Mayo Clinic  Rochester Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymund R.","family":"Razonable","sequence":"additional","affiliation":[{"name":"Division of Public Health, Infectious Diseases, and Occupational Medicine Mayo Clinic  Rochester Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2206573"},{"key":"e_1_2_9_3_1","unstructured":"BhimrajA MorganRL ShumakerAH et al.Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID\u201019.2022."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal3653"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023184"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(20)31022\u20109"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.16349"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116846"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2032369"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2021.11.017"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp2009575"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586\u2010020\u20102521\u20104"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.15957"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003321"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2021.03.010"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac481"},{"key":"e_1_2_9_20_1","doi-asserted-by":"crossref","unstructured":"HaddadTC CoffeyJD DengY et al.Impact of a High\u2010Risk Ambulatory COVID\u201019 Remote Patient Monitoring Program on Utilization Cost and Mortality: Mayo Clin Proc.2022; [published online ahead of print] doi:10.1016\/j.mayocp.2022.08.015.","DOI":"10.1016\/j.mayocp.2022.08.015"}],"container-title":["Influenza and Other Respiratory Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/irv.13136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T15:45:05Z","timestamp":1692459905000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/irv.13136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1111\/irv.13136"],"URL":"https:\/\/doi.org\/10.1111\/irv.13136","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/IRV.13136\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/IRV.13136\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/IRV.13136\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/IRV.13136\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/IRV.13136\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/IRV.13136\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/IRV.13136\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/IRV.13136\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/IRV.13136\/v2\/decision1","asserted-by":"object"}]},"ISSN":["1750-2640","1750-2659"],"issn-type":[{"value":"1750-2640","type":"print"},{"value":"1750-2659","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"2022-10-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e13136"}}